Pune district is among the most affected districts in Maharashtra for COVID-19. (Representational)
Pune:
Resident doctors of Pune s Sassoon General Hospital went on strike today over shortage of manpower at the hospital to treat the growing number of patients.
The emergency services will continue during the protest.
Maharashtra Association of Resident Doctors had written a letter to the hospital administration demanding an increase in the number of health staff to treat patients. The administration however did not respond to any of the demands raised by doctors after which the association has decided to stop non-essential and non-emergency-related services.
The hospital administration has not yet reacted to the situation.
Kochi-based pharma firm s new drug shows promising results against COVID-19
The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore
PB Jayakumar | February 22, 2021 | Updated 15:08 IST
GPP-Baladol, a novel chemical entity (NCE) being developed by pharmaceutical research firm PNB Vesper Life Science for treating Covid-19 patients, claims to have shown promising results in the Phase 2b clinical trials. The pharma firm will soon seek Indian drug regulators approval for emergency use in the country.
The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore. The clinical trial report will be submitted to the DCGI today seeking for an Emergency Use Authorisation to treat hospitalised patients in the country in a clinical trial
PNB Vesper provides potential option to save hospitalised COVID-19 patients globally
PNB Vesper provides potential option to save hospitalised COVID-19 patients globally
12 February 2021 | News
Source credit: Shutterstock
PNB Vesper, a leading Kerala based life sciences company, has announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with oxygen support in September 2020.
The clinical trial was initiated in November 2020 at BJ Government Medical College and Sassoon General Hospital Pune, and Victoria Medical College and Research Institute, Bengaluru. The clinical trial report will now be submitted to DCGI on February 22, 2021.